

For polycythemia vera (PV) in adults who have had an inadequate response to hydroxyurea (HU)¹

INTERVENE — with Jakafi —

to achieve durable count control

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES®) RECOMMENDED

Ruxolitinib (Jakafi) is a preferred treatment option for patients with high-risk PV who have had an inadequate response or loss of response to cytoreductive therapy²

NCCN=National Comprehensive Cancer Network.

INDICATIONS AND USAGE

Jakafi[®] (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

IMPORTANT SAFETY INFORMATION

- Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia, which are each dose-related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
- Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
- Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
- Severe neutropenia (ANC <0.5 × 10⁹/L) was generally reversible by withholding Jakafi until recovery

Please see related and other Important Safety Information on pages 12-13. Please <u>click here</u> for Full Prescribing Information.

For your adult patients on HU and phlebotomy

Proactively identify the characteristics of advanced PV and treat differently

In a subset of patients, these characteristics may indicate advanced PV despite treatment with HU at the maximum tolerated dose and phlebotomy³⁻⁶



"If I have a patient who is encountering challenges strictly maintaining hematocrit levels below 45% and has leukocytosis, this tells me that the hydroxyurea is no longer sufficient."

— Andrew Kuykendall, MD, MPN Expert

Hct=hematocrit; WBC=white blood cell.

IMPORTANT SAFETY INFORMATION (continued)

Risk of infection

- Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines
- Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination
- Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate
- Herpes zoster infection has been reported in patients receiving Jakafi. Advise patients about early signs and symptoms of herpes zoster and to seek early treatment. Herpes simplex virus reactivation and/or dissemination has been reported in patients receiving Jakafi. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment with Jakafi; patients should be promptly treated and monitored according to clinical guidelines
- Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines

NCCN Guidelines® recommend

Actively monitoring patients' response and signs/symptoms of disease progression*

Potential indications for change of cytoreductive therapy for patients with symptomatic low-risk PV or high-risk PV are included in the NCCN Guidelines

NCCN GUIDELINES RECOMMENDED

Monitor patients for new thrombosis or bleeding, response* to cytoreductive therapy, and signs and symptoms* of disease progression²

Potential indications for change of cytoreductive therapy for patients with symptomatic low-risk PV or high-risk PV with no response or loss of response²

- Intolerance or resistance to HU or peginterferon alfa-2a
- Disease-related symptoms
- New thrombosis or disease-related major bleeding
- Progressive thrombocytosis and/or leukocytosis
- Frequent phlebotomy or intolerant of phlebotomy
- Splenomegaly

FDA approved for use in adults with PV after inadequate response to or intolerance of HU¹

- The phase 3 RESPONSE study defined inadequate response to include the maximum tolerated dose of HU, not just the ELN criteria of at least 2 g/d, after 3 months^{7,8}
- RESPONSE was an open-label trial and, therefore, not designed to evaluate a difference in symptoms¹
- The clinical effect of Jakafi[®] (ruxolitinib) on thrombosis has not been established

*Every 3 to 6 months or more frequently as clinically indicated.²

ELN=European LeukemiaNet; RESPONSE=Randomized study of Efficacy and Safety in POlycythemia vera with JAK iNhibitor ruxolitinib verSus bEst available care.





Please see related and other Important Safety Information on pages 12-13. Please <u>click here</u> for Full Prescribing Information.

When PV advances beyond what HU can control, intervene with Jakafi[®] (ruxolitinib)

In the phase 3 RESPONSE* trial, Jakafi demonstrated superior results[†] vs BAT^{1‡}

- **RESPONSE Composite Primary Endpoint**

23% (25/110) reducti

(25/110) of patients receiving Jakafi achieved Hct control and \geq 35% spleen volume reduction at week 32 vs <1% (1/112) of patients receiving BAT (*P*<0.0001)^{1§}

Kaplan-Meier Estimate: Durability of Primary Response at 5 years



Analysis was conducted in week 32 primary responders, beginning at week 32⁹

■ Progression was defined as: the first of 2 consecutive Hct assessments that confirmed phlebotomy eligibility, a spleen volume assessment that was reduced by <35% from the baseline AND that was ≥25% increased at the time of the best-documented spleen volume response, death, or development of MF or acute leukemia¹⁰

66% of patients in the Jakafi arm completed 5 YEARS OF ON-STUDY TREATMENT⁹



"For patients with PV, we know that suboptimal control of hematocrit, which is anything greater than 45% is associated with significant risks, even if the Hct is 47% or 48%. So, to protect my patients, I typically intervene slightly below 45%."

—Ruben Mesa, MD, FACP, MPN Expert

*The RESPONSE trial was a randomized, open-label, active-controlled phase 3 trial comparing Jakafi with BAT in 222 patients with PV. Patients enrolled in the study had been diagnosed with PV for at least 24 weeks, had an inadequate response to or were intolerant of HU, required phlebotomy for Hct control, and exhibited splenomegaly. All patients were required to demonstrate Hct control between 40% and 45% prior to randomization. After week 32, patients on BAT were able to cross over to Jakafi treatment.¹⁸

¹The composite primary endpoint was defined as Hct control without phlebotomy eligibility and a ≥35% spleen volume reduction as measured by CT or MRI. To achieve the Hct control endpoint, patients could not become eligible for phlebotomy between weeks 8 and 32. Phlebotomy eligibility was defined as Hct >45% that is ≥3 percentage points higher than baseline or Hct >48% (lower value).^{1,8}

¹BAT included HU (60%), interferon/pegylated interferon (12%), anagrelide (7%), pipobroman (2%), lenalidomide/thalidomide (5%), and observation (15%).¹ [§]Jakafi: 95% CI, 0.15-0.32; BAT: 95% CI, 0.00-0.05.¹

BAT=best available therapy; CI=confidence interval; CT=computed tomography; MF=myelofibrosis; MRI=magnetic resonance imaging.

More patients achieved Hct control with Jakafi in the absence of phlebotomy eligibility

In the RESPONSE trial, patients on Jakafi achieved a higher rate of Hct control vs BAT¹

0% (66/110) of patients receiving Jakafi achieved Hct control at week 32 vs 19% (21/112) of patients receiving BAT¹

■ To achieve the Hct control endpoint, patients could not become eligible for phlebotomy between weeks 8 and 32. Phlebotomy eligibility was defined as Hct >45% that is ≥3 percentage points higher than baseline or Hct >48% (lower value)^{1,8}

Kaplan-Meier Estimate: Durability of Hct Control at 5 Years



- Analysis was conducted in week 32 Hct control responders, beginning at week 32⁹
- Progression events for the evaluation of duration of absence of phlebotomy eligibility included the first of 2 consecutive Hct assessments that confirmed phlebotomy eligibility, death, or development of MF or acute leukemia¹⁰

BAT=best available therapy.

IMPORTANT SAFETY INFORMATION (continued)

Risk for symptom exacerbation following interruption or discontinuation of Jakafi

When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi-organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation



Please see related and other Important Safety Information on pages 12-13. Please <u>click here</u> for Full Prescribing Information.

Achieved complete hematologic remission with Jakafi[®] (ruxolitinib)

Patients on Jakafi demonstrated significantly higher rates of complete hematologic remission (CHR)* vs BAT¹

RESPONSE Secondary Endpoint

24%

(26/110) of patients receiving Jakafi achieved CHR at week 32 vs 8% (9/112) of patients receiving BAT (*P*=0.0016)^{1†}

Kaplan-Meier Estimate: Durability of CHR at 5 Years



Reprinted from Lancet Haematology. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study (Lancet Haematol. 2020;7(3):e226-e237), doi.org/10.1016/S2352-3026(19)30207-8, with permission from Elsevier.

Analysis was conducted in week 32 CHR responders, beginning at week 32⁹

 Progression events for the evaluation of duration of CHR included first of 2 consecutive Hct assessments that confirmed phlebotomy eligibility, first of 2 contiguous visits during which platelet count was >400 × 10⁹/L or WBC count was >10 × 10⁹/L, death, or development of MF or acute leukemia¹⁰

*CHR was defined as achieving Hct control (as specified in the primary endpoint), platelet count \leq 400 × 10⁹/L, and WBC count \leq 10 × 10⁹/L.¹ ¹Jakafi: 95% CI, 0.16-0.33; BAT: 95% CI, 0.04-0.15.¹ BAT=best available therapy.

IMPORTANT SAFETY INFORMATION (continued)

Other important safety considerations

- Non-melanoma skin cancers (NMSC) including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations
- Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia

Individual component of complete hematologic remission Jakafi reduced mean WBC counts

"It's important in patients with polycythemia vera to establish what their baseline white blood cell count is. Ideally, we want this number to be at or below 11,000 because we understand there's some risk associated with a higher baseline white blood cell count."

— Andrew Kuykendall, MD, MPN Expert



Exploratory analyses from the RESPONSE trial: WBC count data

Mean WBC Counts Over Time⁸



From The New England Journal of Medicine, Vannucchi AM, Kiladjian JJ, Griesshammer M, et al, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, 2015;372(5):426-435. Copyright © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

As shown below, data for patients treated with HU were included in the group of patients receiving BAT¹¹

Mean Change From Baseline in WBC Counts for Patient Subgroups With WBC Counts ≥11 × 10⁹/L¹¹



Figure reproduced with permission from John Wiley & Sons. Harrison CN, Griesshammer M, Miller C, et al. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Br J Haematol. 2018;182(2):279-284.

At baseline, 75.5% of patients (n=83) receiving Jakafi and 71.4% of patients (n=80) receiving BAT had WBC counts ≥11 × 10⁹/L¹¹

BAT=best available therapy.



Please see related and other Important Safety Information on pages 12-13. Please <u>click here</u> for Full Prescribing Information.

Jakafi® (ruxolitinib) symptom data

Exploratory endpoint from the RESPONSE trial

- At week 32, 49% of patients receiving Jakafi and 5% of patients receiving BAT had at least a 50% reduction in the 14-item Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Total Symptom Score⁸
- RESPONSE was an open-label trial and, therefore, not designed to evaluate differences in symptoms¹
- Patient-reported outcomes were assessed using the MPN-SAF symptom diary. The MPN-SAF diary was administered daily in an electronic diary format to score 14 disease-related symptoms on a scale of 0 (absent) to 10 (worst possible). At baseline, median Total Symptom Score was 23.4 (range, 0-106) in the group receiving Jakafi and 33.3 (range, 0-118) in the group receiving BAT^{8,10}

Patients Achieving ≥50% Reduction in MPN-SAF Total Symptom Score at Week 32^{8,a}



From *The New England Journal of Medicine*, Vannucchi AM, Kiladjian JJ, Griesshammer M, et al, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, 2015;372(5):426-435. Copyright © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

^aHigher symptom score indicates greater severity of symptoms. Cytokine symptom cluster includes tiredness, itching, muscle ache, night sweats, and sweating while awake; hyperviscosity symptom cluster includes vision problems, dizziness, concentration problems, headache, numbness or tingling in the hands or feet, ringing in the ears, and skin redness; and splenomegaly symptom cluster includes abdominal discomfort and early satiety. Patients with data at both baseline (value >0) and week 32 were included in this analysis.⁸

BAT=best available therapy.

IMPORTANT SAFETY INFORMATION (continued)

Other important safety considerations (continued)

Another JAK-inhibitor has increased the risk of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and stroke (compared to those treated with tumor TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur

Exploratory endpoint from the RESPONSE trial

Patients receiving Jakafi had greater reductions in all symptom clusters reported, whereas patients receiving BAT had an increase in scores of many symptoms⁸



Median Percent Change in Symptom Score From Baseline to Week 32^{8,a}

This analysis is exploratory in nature and these results should be interpreted with caution.

From *The New England Journal of Medicine*, Vannucchi AM, Kiladjian JJ, Griesshammer M, et al, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, 2015;372(5):426-435. Copyright © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

^aPatients with data at both baseline (value >0) and week 32 were included in this analysis. Negative values indicate a reduction in the severity of symptoms.⁸

BAT=best available therapy.



Safety profile for Jakafi® (ruxolitinib) in PV

RESPONSE nonhematologic adverse reactions¹

| Adverse Reactions (Incidence ≥5%) | Jakaf | i (n=110) | BAT (n=111) | | |
|---|----------------|-------------------|--------------------|-------------------|--|
| | All Grades,ª % | Grades 3 and 4, % | All Grades, % | Grades 3 and 4, % | |
| Diarrhea | 15 | 0 | 7 | <1 | |
| Dizziness ^b | 15 | 0 | 13 | 0 | |
| Dyspnea⁰ | 13 | 3 | 4 | 0 | |
| Muscle spasms | 12 | <1 | 5 | 0 | |
| Constipation | 8 | 0 | 3 | 0 | |
| Herpes zoster ^d | 6 | <1 | 0 | 0 | |
| Nausea | 6 | 0 | 4 | 0 | |
| Weight gain ^e | 6 | 0 | <1 | 0 | |
| Urinary tract infections ^f | 6 | 0 | 3 | 0 | |
| Hypertension | 5 | <1 | 3 | <1 | |

aNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

^bIncludes dizziness and vertigo.

°Includes dyspnea and dyspnea exertional.

^dIncludes herpes zoster and postherpetic neuralgia.

eIncludes weight increased and abnormal weight gain.

^fIncludes urinary tract infection and cystitis.

BAT=best available therapy.

IMPORTANT SAFETY INFORMATION (continued)

Other important safety considerations (continued)

- Another JAK-inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. In patients with myelofibrosis (MF) and polycythemia vera (PV) treated with Jakafi in clinical trials, the rates of thrombosis should be promptly evaluated and treated appropriately
- Another JAK-inhibitor has increased the risk of lymphoma and other malignancies excluding NMSC (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. Patients who are current or past smokers are at additional increased risk. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi, particularly in patients with a known secondary malignancy (other than a successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers

| Laboratory Parameter ^a | Jakafi (n=110) | | | BAT (n=111) | | | | | |
|--------------------------------------|----------------------------|------------|------------|--------------------|------------|------------|--|--|--|
| | All Grades, ^b % | Grade 3, % | Grade 4, % | All Grades, % | Grade 3, % | Grade 4, % | | | |
| Hematology | | | | | | | | | |
| Anemia | 72 | <1 | <1 | 58 | 0 | 0 | | | |
| Thrombocytopenia | 27 | 5 | <1 | 24 | 3 | <1 | | | |
| Neutropenia | 3 | 0 | <1 | 10 | <1 | 0 | | | |
| Chemistry | | | | | | | | | |
| Hypercholesterolemia | 35 | 0 | 0 | 8 | 0 | 0 | | | |
| Elevated ALT | 25 | <1 | 0 | 16 | 0 | 0 | | | |
| Elevated AST | 23 | 0 | 0 | 23 | <1 | 0 | | | |
| Hypertriglyceridemia | 15 | 0 | 0 | 13 | 0 | 0 | | | |

Clinically relevant laboratory abnormalities¹

^aPresented values are worst grade values regardless of baseline.

^bNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.

Discontinuation for adverse events, regardless of causality, was observed in 4% of patients treated with Jakafi¹

ALT=alanine transaminase; AST=aspartate transaminase; BAT=best available therapy.

IMPORTANT SAFETY INFORMATION (continued)

Other important safety considerations (continued)

- In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema. In chronic graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >20%) were infections (pathogen not specified) and viral infections
- Avoid concomitant use with fluconazole doses greater than 200 mg. Dose modifications may be required when administering Jakafi with fluconazole doses of 200 mg or less, or with strong CYP3A4 inhibitors, or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
- Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breastfeed during treatment and for 2 weeks after the final dose



Please see related and other Important Safety Information on pages 12-13. Please <u>click here</u> for Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

- Treatment with Jakafi[®] (ruxolitinib) can cause thrombocytopenia, anemia and neutropenia, which are each dose-related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated
- Manage thrombocytopenia by reducing the dose or temporarily interrupting Jakafi. Platelet transfusions may be necessary
- Patients developing anemia may require blood transfusions and/or dose modifications of Jakafi
- Severe neutropenia (ANC <0.5 × 10⁹/L) was generally reversible by withholding Jakafi until recovery
- Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines
- Tuberculosis (TB) infection has been reported. Observe patients taking Jakafi for signs and symptoms of active TB and manage promptly. Prior to initiating Jakafi, evaluate patients for TB risk factors and test those at higher risk for latent infection. Consult a physician with expertise in the treatment of TB before starting Jakafi in patients with evidence of active or latent TB. Continuation of Jakafi during treatment of active TB should be based on the overall risk-benefit determination
- Progressive multifocal leukoencephalopathy (PML) has occurred with Jakafi treatment. If PML is suspected, stop Jakafi and evaluate
- Herpes zoster infection has been reported in patients receiving Jakafi. Advise patients about early signs and symptoms of herpes zoster and to seek early treatment. Herpes simplex virus reactivation and/or dissemination has been reported in patients receiving Jakafi. Monitor patients for the development of herpes simplex infections. If a patient develops evidence of dissemination of herpes simplex, consider interrupting treatment with Jakafi; patients should be promptly treated and monitored according to clinical guidelines
- Increases in hepatitis B viral load with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic hepatitis B virus (HBV) infections. Monitor and treat patients with chronic HBV infection according to clinical guidelines
- When discontinuing Jakafi, myeloproliferative neoplasm-related symptoms may return within one week. After discontinuation, some patients with myelofibrosis have experienced fever, respiratory distress, hypotension, DIC, or multi-organ failure. If any of these occur after discontinuation or while tapering Jakafi, evaluate and treat any intercurrent illness and consider restarting or increasing the dose of Jakafi. Instruct patients not to interrupt or discontinue Jakafi without consulting their physician. When discontinuing or interrupting Jakafi for reasons other than thrombocytopenia or neutropenia, consider gradual tapering rather than abrupt discontinuation
- Non-melanoma skin cancers (NMSC) including basal cell, squamous cell, and Merkel cell carcinoma have occurred. Perform periodic skin examinations

IMPORTANT SAFETY INFORMATION (continued)

- Treatment with Jakafi has been associated with increases in total cholesterol, low-density lipoprotein cholesterol, and triglycerides. Assess lipid parameters 8-12 weeks after initiating Jakafi. Monitor and treat according to clinical guidelines for the management of hyperlipidemia
- Another JAK-inhibitor has increased the risk of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, and stroke (compared to those treated with tumor TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur
- Another JAK-inhibitor has increased the risk of thrombosis, including deep venous thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. In patients with myelofibrosis (MF) and polycythemia vera (PV) treated with Jakafi in clinical trials, the rates of thromboembolic events were similar in Jakafi and control treated patients. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately
- Another JAK-inhibitor has increased the risk of lymphoma and other malignancies excluding NMSC (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which Jakafi is not indicated. Patients who are current or past smokers are at additional increased risk. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with Jakafi, particularly in patients with a known secondary malignancy (other than a successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers
- In myelofibrosis and polycythemia vera, the most common nonhematologic adverse reactions (incidence ≥15%) were bruising, dizziness, headache, and diarrhea. In acute graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >50%) were infections (pathogen not specified) and edema. In chronic graft-versus-host disease, the most common nonhematologic adverse reactions (incidence >20%) were infections (pathogen not specified) and viral infections
- Avoid concomitant use with fluconazole doses greater than 200 mg. Dose modifications may be required when administering Jakafi with fluconazole doses of 200 mg or less, or with strong CYP3A4 inhibitors, or in patients with renal or hepatic impairment. Patients should be closely monitored and the dose titrated based on safety and efficacy
- Use of Jakafi during pregnancy is not recommended and should only be used if the potential benefit justifies the potential risk to the fetus. Women taking Jakafi should not breastfeed during treatment and for 2 weeks after the final dose



Jakafi[®] (ruxolitinib) targets the primary driver of PV¹





JAK1

Plays a major role in signaling of key proinflammatory cytokines¹²

JAK=Janus kinase; STAT=signal transducer and activator of transcription.

JAK2

Mediates signals for hematopoietic growth factors¹²

IMPORTANT SAFETY INFORMATION (continued)

Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia, which are each dose-related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated

Individualized dosing for Jakafi



START: For patients with PV who have an inadequate response to HU, the recommended starting dose is 10 mg twice daily. A CBC must be performed before initiating Jakafi¹

Special Populations

For patients with renal or hepatic impairment or receiving concomitant strong CYP3A4 inhibitors or fluconazole, please refer to the Full Prescribing Information for starting dose, other dose modifications, and when to avoid treatment with Jakafi.¹

- Avoid fluconazole doses of >200 mg daily with Jakafi¹
- Avoid use of Jakafi in patients with end-stage renal disease (creatinine clearance, <15 mL/min) not requiring dialysis¹





MONITOR: A CBC must be performed before initiating Jakafi, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated¹



OPTIMIZE: Individualize dosing of Jakafi to optimize balance between safety and efficacy¹

- Dosing may be reduced or temporarily interrupted based on hemoglobin, platelet, or neutrophil counts¹
- Additionally, dosing may be increased to achieve desired clinical response¹
- Interrupt treatment for bleeding¹

CBC=complete blood count.

References: 1. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 24, 2023. To view the most recent and complete version of the guideline, go online to NCCN. org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513-520. 4. Marchioli R, Finazzi G, Specchia G, et al; for CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33. 5. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560-561. 6. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103. 7. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770. 8. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. Supplementary appendix available at: https://www.nejm.org/doi/suppl/10.1056/NEJMoa1409002/suppl_file/nejmoa1409002_appendix.pdf. 9. Kiladjian J-J, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):e226-e237. Supplementary appendix available at: doi:10.1016/S2352-3026(19)30207-8. 10. Data on file. Incyte Corporation. Wilmington, DE. 11. Harrison CN, Griesshammer M, Miller C, et al. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Br J Haematol. 2018;182(2):279-284. Supplemental information available at: https://onlinelibrary.wiley.com/doi/10.1111/bjh.14764. 12. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117. 13. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680-692. 14. Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol. doi:10.1186/s40164-016-0031-8. 15. Mascarenhas J. A concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2016;16(suppl):S124-S129. 16. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961-963. 17. Michiels JJ, Berneman Z, Schroyens W, Lam KH, De Raeve H. PVSG and WHO vs European Clinical, Molecular and Pathological Criteria for prefibrotic myeloproliferative neoplasms. World J Hematol. 2013;2(3):71-88.

Please see related and other Important Safety Information on pages 12-13. Please <u>click here</u> for Full Prescribing Information.



PV is a hematologic malignancy that can become advanced in a subset of patients^{6,13-17}

WBC count

 $>11 \times 10^{9}/L$

Proactively identify the subset of patients with characteristics of advanced PV despite treatment with HU at the maximum tolerated dose and phlebotomy, and treat differently³⁻⁶

"I think it's important to identify patients who may be appropriate for Jakafi. These may be patients who are struggling to maintain hematocrit less than 45% and/or having leukocytosis. In addition, for those patients who also have disease-related symptoms such as fatigue, pruritus, night sweats at the maximum tolerated dose of hydroxyurea, and frequent phlebotomies, I typically intervene with Jakafi."



OR

Indications and Usage

Hct

≥45%

PLUS

Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.

Important Safety Considerations

- Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia, which are each dose-related effects. Perform a pre-treatment complete blood count (CBC) and monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. In patients with cytopenias, consider dose reductions, temporarily interrupting Jakafi or transfusions, as clinically indicated
- Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines

Please see related and other Important Safety Information on pages 12-13. Please <u>click here</u> for Full Prescribing Information.

hcp.jakafi.com



Incyte and the Incyte logo are registered trademarks of Incyte. Jakafi and the Jakafi logo are registered trademarks of Incyte. All other trademarks are the property of their respective owners. © 2023, Incyte. MAT-JAK-04221 02/23



Disease-related

symptoms